clinical trial · NCT02939820
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, FamilialFamilial Amyloid PolyneuropathiesAmyloid NeuropathiesAmyloidosis, Hereditary, Transthyretin-Relatedpatisiran (ALN-TTR02)
brief summary
The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).
started
—
primary completion
—
completion
—
last updated
May 20, 2024
detailed description
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the links provided in More Information.
official title
Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol